Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma
- Conditions
- recurrent glioblastomaMedDRA version: 19.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2017-000200-23-BE
- Lead Sponsor
- Z Brussel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 54
1.Diagnosis:
•Histologically confirmed diagnosis of World Health Organization Grade IV malignant glioma (glioblastoma or gliosarcoma);
•Documentation of recurrent (or progressive according to RNAO criteria) glioblastoma following prior treatment with surgery (resection or biopsy), radiation therapy and temozolomide chemotherapy;
•A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or 15 unstained slides (10 minimum) obtained from an archival FFPE tumor tissue block will be required.
•Presence of a measurable tumor lesion that is characterized by gadolinium enhancement on T1-MRI of the brain (with a shortest diameter of >5 mm) and enhanced lesion to normal brain uptake on FET-PET imaging of the brain;
•If first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field.
•An interval of >28 days and full recovery (ie, no ongoing safety issues) from surgical resection and an interval of >4 weeks after the last administration of any other treatment for glioblastoma.
2.Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative, as allowed by local guidance/practice) has been informed of all pertinent aspects of the study.
3.Patients who are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
4.Age 18 years.
5.Estimated life expectancy of at least 3 months.
6.Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
7.No evidence of pre-existing uncontrolled hypertension as documented by 2 baseline blood pressure (BP) readings taken at least 1 hour apart. The baseline systolic BP readings must be ?140 mm Hg, and the baseline diastolic BP readings must be ?90 mm Hg. Use of antihypertensive medications to control BP is allowed.
8.Adequate bone marrow function, including:
a. Absolute neutrophil count (ANC) ?1,500/mm3 or ?1.5 x 109/L;
b. Platelets ?100,000/mm3 or ?100 x 109/L;
c. Hemoglobin ?9 g/dL (may have been transfused).
9.Adequate renal function, including:
a.Estimated creatinine clearance = 30 mL/min as calculated using the Cockcroft-Gault (CG) equation;
b.Urinary protein <2+ by urine dipstick. If dipstick is ?2+, then 24-hour urinary protein <2 g per 24 hours.
10.Adequate liver function, including:
a.Total serum bilirubin ?1.5 x upper limit of normal (ULN);
b.AST and ALT ?2.5 x ULN.
11.Serum pregnancy test (for females of childbearing potential) negative at screening.
12.Male patients able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 90 days after the last dose of assigned treatment.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 26
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 26
1.Any of the following prior cancer therapies:
•Prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways;
•Prior therapy with axitinib as well as any prior therapies with other VEGF pathway inhibitors (including bevacizumab)
2.Participation in other therapeutic studies within 4 weeks prior to enrollment in the current study
3.Persisting toxicity related to prior therapy NCI CTCAE v4.03 Grade >1; however, sensory neuropathy Grade =2 is acceptable
4.Current or prior use of immunosuppressive medication within 7 days prior to enrollment, except for steroid treatment needed to palliate glioblastoma associated neurological symptoms and intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection);
5.No treatment with enzyme inducing anti-epileptic drugs (EIAED) during and at least 14 days before the administration of axitinib
6.Known severe hypersensitivity reactions to monoclonal antibodies (Grade >3), any history of anaphylaxis
7.Known prior or suspected hypersensitivity to study drugs or any component in their formulations
8.Diagnosis of any other malignancy within 5 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation or castration)
9.Active autoimmune disease that might deteriorate when receiving an immunostimulatory agents. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
10.Gastrointestinal abnormalities including:
•Inability to take oral medication;
•Requirement for intravenous alimentation;
•Prior surgical procedures affecting absorption including total gastric resection;
•Treatment for active peptic ulcer disease in the past 6 months;
•Active gastrointestinal bleeding, unrelated to cancer, as evidenced by clinically significant hematemesis, hematochezia or melena
•Malabsorption syndromes
11.Active infection requiring systemic therapy
12.Diagnosis of prior immunodeficiency or organ transplant requiring immunosuppressive therapy, or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
13.Any test for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating acute or chronic infection
14.Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines)
15.Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed
16.Evidence of inadequate wound healing (including dehiscence of the craniotomy scar)
17.Grade 3 hemorrhage within 4 weeks of patient enrollment
18.Any of the following in the previous 12 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, LVEF less than LLN, clinically significant perica
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method